Department of Medicine, UT Health at San Antonio, TX, United States.
VA Biomedical Laboratory Research, South Texas Veterans Health Care System, San Antonio, TX, United States; Department of Pathology, UT Health at San Antonio, TX, United States.
Cell Signal. 2018 Jan;42:44-53. doi: 10.1016/j.cellsig.2017.09.017. Epub 2017 Sep 23.
Glomerular mesangial cell hypertrophy contributes to the complications of diabetic nephropathy. The mechanism by which high glucose induces mesangial cell hypertrophy is poorly understood. Here we explored the role of the platelet-derived growth factor receptor-β (PDGFRβ) tyrosine kinase in driving the high glucose-induced mesangial cell hypertrophy. We show that high glucose stimulates the association of the PDGFRβ with PI 3 kinase leading to tyrosine phosphorylation of the latter. High glucose-induced Akt kinase activation was also dependent upon PDGFRβ and its tyrosine phosphorylation at 740/751 residues. Inhibition of PDGFRβ activity, its downregulation and expression of its phospho-deficient (Y740/751F) mutant inhibited mesangial cell hypertrophy by high glucose. Interestingly, expression of constitutively active Akt reversed this inhibition, indicating a role of Akt kinase downstream of PDGFRβ phosphorylation in this process. The transcription factor Hif1α is a target of Akt kinase. siRNAs against Hif1α inhibited the high glucose-induced mesangial cell hypertrophy. In contrast, increased expression of Hif1α induced hypertrophy similar to high glucose. We found that inhibition of PDGFRβ and expression of PDGFRβ Y740/751F mutant significantly inhibited the high glucose-induced expression of Hif1α. Importantly, expression of Hif1α countered the inhibition of mesangial cell hypertrophy induced by siPDGFRβ or PDGFRβ Y740/751F mutant. Finally, we show that high glucose-stimulated PDGFRβ tyrosine phosphorylation at 740/751 residues and the tyrosine kinase activity of the receptor regulate the transforming growth factor-β (TGFβ) expression by Hif1α. Thus we define the cell surface PDGFRβ as a major link between high glucose and its effectors Hif1α and TGFβ for induction of diabetic mesangial cell hypertrophy.
肾小球系膜细胞肥大是糖尿病肾病并发症的原因之一。高血糖诱导系膜细胞肥大的机制尚不清楚。在这里,我们探讨了血小板衍生生长因子受体-β(PDGFRβ)酪氨酸激酶在驱动高葡萄糖诱导的系膜细胞肥大中的作用。我们发现,高葡萄糖刺激 PDGFRβ与 PI 3 激酶结合,导致后者的酪氨酸磷酸化。高葡萄糖诱导的 Akt 激酶激活也依赖于 PDGFRβ及其在 740/751 残基处的酪氨酸磷酸化。PDGFRβ 活性的抑制、其下调和表达其磷酸缺陷(Y740/751F)突变体抑制了高葡萄糖诱导的系膜细胞肥大。有趣的是,组成型激活 Akt 的表达逆转了这种抑制,表明在这个过程中,Akt 激酶在 PDGFRβ 磷酸化的下游起作用。转录因子 Hif1α 是 Akt 激酶的靶标。针对 Hif1α 的 siRNA 抑制了高葡萄糖诱导的系膜细胞肥大。相反,Hif1α 的表达增加诱导了类似于高葡萄糖的肥大。我们发现,PDGFRβ 的抑制和 PDGFRβ Y740/751F 突变体的表达显著抑制了高葡萄糖诱导的 Hif1α 表达。重要的是,Hif1α 的表达抵消了 siPDGFRβ 或 PDGFRβ Y740/751F 突变体诱导的系膜细胞肥大抑制作用。最后,我们表明,高葡萄糖刺激 PDGFRβ 在 740/751 残基处的酪氨酸磷酸化和受体的酪氨酸激酶活性通过 Hif1α 调节转化生长因子-β(TGFβ)的表达。因此,我们将细胞表面 PDGFRβ 定义为高葡萄糖与其效应物 Hif1α 和 TGFβ 之间的主要联系,用于诱导糖尿病系膜细胞肥大。